18,536 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Machina Capital S.A.S.

Machina Capital S.A.S. bought a new position in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 18,536 shares of the medical equipment provider’s stock, valued at approximately $1,072,000.

A number of other hedge funds have also bought and sold shares of BSX. FMR LLC increased its stake in Boston Scientific by 6.8% in the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after purchasing an additional 8,045,263 shares in the last quarter. American Century Companies Inc. increased its stake in Boston Scientific by 391.6% in the third quarter. American Century Companies Inc. now owns 3,271,810 shares of the medical equipment provider’s stock valued at $172,752,000 after purchasing an additional 2,606,253 shares in the last quarter. Wellington Management Group LLP increased its stake in Boston Scientific by 5.9% in the third quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock valued at $2,221,641,000 after purchasing an additional 2,336,348 shares in the last quarter. Winslow Capital Management LLC increased its stake in Boston Scientific by 39.3% in the third quarter. Winslow Capital Management LLC now owns 6,129,573 shares of the medical equipment provider’s stock valued at $323,641,000 after purchasing an additional 1,730,133 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Boston Scientific by 1.2% in the third quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock valued at $6,534,969,000 after purchasing an additional 1,525,432 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 17,587 shares of Boston Scientific stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total value of $1,257,470.50. Following the completion of the sale, the executive vice president now directly owns 50,638 shares in the company, valued at $3,620,617. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now owns 56,508 shares in the company, valued at approximately $3,779,820.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 17,587 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company’s stock, valued at approximately $3,620,617. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 78,384 shares of company stock worth $5,395,560. 0.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Raymond James boosted their target price on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research report on Thursday, April 25th. Oppenheimer boosted their target price on shares of Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, February 1st. Citigroup boosted their price target on shares of Boston Scientific from $79.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Argus boosted their price target on shares of Boston Scientific from $69.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. boosted their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $75.09.

Boston Scientific Stock Up 1.2 %

Boston Scientific stock traded up $0.88 during mid-day trading on Tuesday, reaching $73.43. The stock had a trading volume of 4,095,367 shares, compared to its average volume of 6,596,280. Boston Scientific Co. has a one year low of $48.35 and a one year high of $74.39. The company has a 50-day moving average price of $68.54 and a two-hundred day moving average price of $61.57. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. The company has a market capitalization of $107.73 billion, a price-to-earnings ratio of 60.97, a PEG ratio of 2.51 and a beta of 0.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.